EMEA-001186-PIP01-11-M02

Key facts

Invented name
Iclusig
Active substance
ponatinib
Therapeutic area
Oncology
Decision number
P/0293/2018
PIP number
EMEA-001186-PIP01-11-M02
Pharmaceutical form(s)
  • Film-coated tablet
  • Capsule, hard
  • Age-appropriate formulation
Condition(s) / indication(s)
  • Treatment of acute lymphoblastic leukaemia
  • Treatment of chronic myeloid leukaemia
Route(s) of administration
Oral use
Contact for public enquiries
Incyte Biosciences Distribution B.V.

E-mail: globalmedinfo@incyte.com
Tel. +800 0002 7423

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating